Cape Town – A total of 1,422 new cases linked to Covid-19 have been identified in South Africa.
The cumulative number of Covid-19 cases now stands at 1,548,157, Health Minister Zweli Mkhize said in a statement Wednesday evening. In total, 756 new cases of Covid-19 were reported on Tuesday and 548 on Monday.
A total of 58 other Covid-19-related deaths have been reported (up from 78 yesterday): Gauteng 23, KwaZulu-Natal 23, Western Cape 9, Northern Cape 2 and Free State 1. No deaths have been recorded in Cape Town oriental, Limpopo, Mpumalanga and North-West.
The death toll from Covid-19 now stands at 52,846. Cumulative recoveries have increased to 1,474,319, or a recovery rate of 95%.
The cumulative total of tests performed is 9,879,348, including 34,513 tests since the last report.
Visiting hours at Gauteng government hospitals have been lightened to allow one visitor per patient for 15 minutes.
“The amendment will allow relatives and friends of patients to spend time with loved ones while adhering to non-pharmaceutical Covid-19 measures such as social distancing and minimizing overcrowding and congestion in hospitals,” the department said. provincial health.
Several restaurants in KwaZulu-Natal achieved Green Flag status on Wednesday when their existing Covid-19 protocols were certified by the new GreenFlag association.
Similar to the Blue Flag status achieved by beaches, GreenFlag certification for public spaces is meant to provide assurance that a place has taken every precaution to provide a safe public space for guests and staff, especially when it is in use. provides adequate ventilation.
Pfizer Inc and BioNTech SE said on Wednesday that their Covid-19 vaccine was safe and effective and produced robust antibody responses in children 12 to 15 years old, paving the way for a US emergency use authorization within weeks. .
Pfizer is hoping the group’s vaccinations could begin before the next school year, Albert Bourla, chairman and chief executive officer of Pfizer, said in a statement.
Pfizer’s vaccine is already approved for people aged 16 and over. The new study offers the first evidence of how the vaccine will also work in school-aged adolescents.
In the trial of 2,260 adolescents aged 12 to 15, there were 18 cases of Covid-19 in the group that received a placebo and none in the group that received the vaccine, resulting in efficacy of 100% in the prevention of Covid-19.
The vaccine was well tolerated, with side effects similar to those seen in people aged 16 to 25 in the adult trial. He did not list side effects for the younger group, but side effects from the adult trial were generally mild to moderate and included injection site pain, headache, fever, and pain. tiredness.